Trial reportHaematologica2017
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Open access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Annals of hematology · 2021Trial
- Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.Blood advances · 2026Article
- Review
- MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-β1 and LRP6 pathways.Haematologica · 2026Article
- Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation.MedComm · 2026Article
- TRPM7 and magnesium orchestrate human CD4 T-cell activation and differentiation.Life science alliance · 2026Article
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Regulation of Treg cells by cytokine signaling and co-stimulatory molecules.Frontiers in immunology · 2024Review
- Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.Blood advances · 2022Article
- Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.Frontiers in immunology · 2022Review
- Recipient Tregs: Can They Be Exploited for Successful Hematopoietic Stem Cell Transplant Outcomes?Frontiers in immunology · 2022Review
- Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.Immunology · 2021Article
- New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).Expert opinion on therapeutic targets · 2021Review
- Review
- Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD).Cellular immunology · 2021Article
- Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Article
- T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?Frontiers in immunology · 2021Review
- Review
- Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Brian C BettsDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA brian.betts@moffitt.org.
Joseph PidalaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Jongphil KimDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Asmita MishraDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Taiga NishihoriDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Lia PerezDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Jose Leonel Ochoa-BayonaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Farhad KhimaniDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Kelly WaltonDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Ryan BookoutDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Michael NiederDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Divis K KhairaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Marco DavilaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Melissa AlsinaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Teresa FieldDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Ernesto AyalaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Frederick L LockeDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Marcie RichesDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Mohamed Kharfan-DabajaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Hugo FernandezDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Claudio AnasettiDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
Moffitt Cancer Center · US
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MNCI NIH HHS K12 CA090625NCI NIH HHS P30 CA076292
Abstract
Graft-
Indexed as
AdultAgedAntibiotics, AntineoplasticDrug Administration ScheduleFemaleGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansInterleukin-2MaleMiddle AgedNeoplasm Recurrence, LocalSirolimusSurvival AnalysisT-Lymphocytes, RegulatoryAntibiotics, AntineoplasticInterleukin-2Sirolimus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.